COMPLICATIONS OF EMERGING SURGICAL PROCEDURES

Samir Melki, MD, PhD
MODERATOR

Jeremy Kieval, MD
PROGRAM COMMITTEE COORDINATOR

SUBSPECIALTY SESSIONS: NEURO-OPHTHALMOLOGY

Thomas Hedges, MD
MODERATOR

UVEITIS MASQUERADES

Nicholas Butler, MD
MODERATOR

Michael Yoon, MD
PROGRAM COMMITTEE COORDINATOR

NEOS ANNUAL HECHT POSTER CONTEST

Donna Siracuse-Lee, MD
MODERATOR

JUNE 1, 2018
Back Bay Event Center
180 BERKELEY STREET | BOSTON, MA 02110
COMPlications of EMERging SURGICAL PROCEDURES!

Samir Melki, MD, PhD, Moderator
Jeremy Kieval, MD, Program Committee Coordinator

SUBSPECIALTY SESSIONS:
NEURO-OPHTHALMOLOGY
Thomas Hedges, MD, Moderator

UVEITIS MASQUERADES
Nicholas Butler, MD,
Michael Yoon, MD, Program Committee Coordinator

NEOS ANNUAL HECHT POSTER CONTEST
Donna Siracuse-Lee, MD,

Accreditation:
Accreditation: The New England Ophthalmological Society designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The New England Ophthalmological Society is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.
PRESIDENT’S MESSAGE

While I am unable to be with you at this June NEOS meeting, as I am out of the country on yet another medical mission, I wanted to take this opportunity to review the accomplishments of the Executive Board of NEOS for this past year. It has been an exciting year to have led NEOS as its President. Your Board has been proactive in developing an ad hoc CME Board Seat which was recognized by our accrediting organization which saw its way to grant NEOS another 4 years re-accreditation for its CME credits. This, was essentially, the longest available re accreditation term available for an organization of our nature. We also developed an ad hoc Board seat for the Young Ophthalmologist Committee. Your Board considers this new Committee to be a cornerstone of the future development of our membership. Hence, its important is reflected in the development of its Board seat. In addition, your Board developed bylaw changes to elect Members in Training and allowing them NEOS status so that they have access to the Freeman Video Library and meetings. We were active in awarding the Distinguished Achievement Award to Dr. Langston this past April. Furthermore, your Board has finally moved to a more electronic format for its meetings. And as always, the Program Committee has been exceptional in leading us to excellent sessions throughout this past year. Compliments to all on the Program Committee, especially its Chairperson, Dr. Joel Geffin.

Finally, I would like to take this opportunity to thank all the members of NEOS for allowing me to become President this year. It has been an honor and privilege to serve as your President. Enjoy your meeting, posters, Grand Rounds, and collegiality.

Yours in NEOS,

John J. Dagianis, MD
President
AMAR AGARWAL, MS, FRCS, FRCOphth

Past President- International Society of Refractive surgery (ISRS)
Secretary General- Indian Intraocular Implant and Refractive Society (IIRSI)

Amar Agarwal is the pioneer of Phakonit which is Phako with a Needle Incision Technology. This technique became popularized as Bimanual phaco, Microincision cataract surgery (MICS) or Microphaco. He is the first to remove cataracts through a 0.7 mm tip with the technique called Microphakonit. He has also discovered No anesthesia cataract surgery and FAVIT a new technique to remove dropped nuclei. The air pump which was a simple idea of using an aquarium fish pump to increase the fluid into the eye in bimanual phaco and co-axial phaco has helped prevent surge. This built the basis of various techniques of forced infusion for small incision cataract surgery. He has also discovered a new refractive error called Aberropia. He has also been the first to do a combined surgery of microphonakonit (700 micron cataract surgery) with a 25 gauge vitrectomy in the same patient thus having the smallest incisions possible for cataract and vitrectomy. He is also the first surgeon to implant a new mirror telescopic IOL (LMI) for patients suffering from age related macular degeneration. He has also been the first in the world to implant a Glued IOL. In this a PC IOL is fixed in an eye without any capsules using fibrin glue. The Malyugin ring for small pupil cataract surgery was also modified by him as the Agarwal modification of the Malyugin ring for miotic pupil cataract surgeries with posterior capsular defects. Dr. Agarwal’s eye hospital has also done for the first time an Anterior segment transplantation in a 4 month old child with anterior staphyloma. He also has brought out the technique of IOL Scaffold in which a three piece IOL is injected into an eye between the iris and the nucleus to prevent the nucleus from falling down in posterior capsular ruptures. He has combined Glued IOL and IOL scaffold in cases of PC rupture where there is no iris or capsular support and termed the technique Glued IOL Scaffold. Dr Agarwal's eye hospital has also done for the first time a glued endocapsular ring in cases of subluxated cataract.

Pre Descemet’s Endothelial Keratoplasty or PDEK was started by Prof Agarwal. In this the Pre Descemets layer and the Descemet’s membrane with endothelium are transplanted en bloc in patients with diseased endothelium. Dr Agarwal’s eye hospital has also done for the first time CACXL or Contact lens assisted collagen cross linking a new technique for cross linking thin corneas and have also worked on E PDEK in which an endoilluminator is used to assist in PDEK surgeries. Dr Agarwal has designed the new instrument called the Trocar anterior chamber maintainer now in complicated cases which helps give infusion through the anterior chamber and works like a trocar cannula. He has also started a new technique of iris suturing called Single pass Four Throw (SFT) pupilloplasty. This is used for closed angle glaucoma and for mydriatic cases.

Dr. Agarwal has performed more than 150 live surgeries at various conferences. His videos have won many awards at the film festivals of ASCRS, AAO and ESCRS. He has also written more than 60 books which have been published in various languages- English, Spanish and Polish. He also trains doctors from all over the world in his center on phaco, glued IOL, lasik and retinal surgeries. He is Chairman and managing director of Dr. Agarwals group of eye hospitals which has 75 eye hospitals all over the world.
COMPLICATIONS OF EMERGING SURGICAL PROCEDURES

Moderator: Samir Melki, MD, PhD
Program Committee Coordinator: Jeremy Kieval, MD

Professional Practice Gaps:
Using feedback from NEOS members and discussion by the Program Committee, we have identified the following practice gaps: New complications emerging with new techniques; prevention measure associated with a new set of complications; management of new complications not in current armamentarium.

NEOS Program Objectives:
The content and format of this educational activity has been specifically designed to fill the practice gaps in the audience’s current and potential scope of profession activities by: Identifying complications associated with emerging surgical procedures; discuss etiology and prevention of a new set of unfamiliar complications; to prepare the surgeon to better manage a new set of complication as they embrace new surgical techniques.

7:00 am  Registration/Exhibits
7:30-8:30  NEOS GRAND ROUNDS – Freedom Room – Lower Level
7:30  Best of the NEOS Hal Freeman Video Library – MAIN HALL
8:30  Introduction.................................................................Samir Melki, MD, PhD
8:35  The Latest in Corneal Surgery:  
Climbing the Steep Learning Curve.................................Joseph Williams, MD
8:50  New Refractive Frontiers: Facing the Unexpected........Jason Brenner, MD
9:05  Emerging Glaucoma Surgery:  
Lower IOP without Raising the Risk.................................Susan Liang, MD
9:20  Introduction of Guest of Honor.........................Samir Melki, MD, PhD
9:25  Glued IOLs, IOL Scaffold and Other  
Anterior Segment Acrobatics.............Amar Agarwal, MS, FRCS, FRCOphth
9:50  Business Meeting
10:00  Refreshment break / Exhibits
10:30  Oculoplastics: Risks and Perils of  
Novel Procedures.........................................................John Mandeville, MD
10:45  What’s Emerging Behind the Lens: New Retina  
Procedures and associated Pitfalls .....................Archana Seethala, MD
11:00  Corneal Transplantation with Pre-Descemets Endothelial Keratoplasty and Single Pass 4 Throw Pupilloplasty: Bold and Beautiful .................. Amar Agarwal, MS, FRCS, FRCOphth

11:25  Questions and Panel Discussion ............ Samir Melki, MD, PhD, Moderator
       Amar Agarwal  John Mandeville, MD
       Jason Brenner, MD  Archana Seethala MD
       Susan Liang, MD  Joseph Williams, MD

11:45  LUNCHEON SEMINARS:

I.  I. Young Ophthalmologists Luncheon I - What I should have said… How to Discuss Complications with Patients.
       Drs. Carolyn Kloek and Chandru Krishnan
       Freedom Room

This luncheon is open to all, there is no fee, and no CME credit, but must be preregistered

II.  Cornea and Anterior Segment Disasters
       Dr. Amar Agarwal
       Patriot Room

Accreditation: The New England Ophthalmological Society designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The New England Ophthalmological Society is accredited by the Massachusetts Medical Society to provide continuing medical education for physicians.
NEURO-OPHTHALMOLOGY

Moderator: Thomas Hedges, MD  
Program Committee Coordinator: Michael Yoon, MD

Professional Practice Gaps: Using feedback from NEOS members and Program committee, attendees need more information regarding tests used to evaluate neuro-ophthalmic disorders, especially neuroradiology, electrophysiology and serum analysis for genetic defects and infectious.

NEOS Program Objectives:  
The content and format of this education activity has been specifically designed to fill the practice gaps in the audience’s current and potential scope of profession activities by:

1. Reviewing when and how to order MRI and CT scans;  
2. Discussing when to get genetic and antibody tests;  
3. Recommending OCT, visual field and electrophysiology tests.

1:00 pm Introduction.................................Thomas Hedges, MD
1:05 CAT: Still Useful?.................................Joseph Rizzo, MD
1:20 MRI: How to Order the Right One..............Bart Chwalisz, MD
1:35 Genetic Testing for Neuro-ophthalmic Disorders........Marc Bouffard, MD
1:50 Antibody Testing for Neuro-ophthalmology........Crandall Peeler, MD
2:05 Refreshment Break/Exhibits
2:35 OCT for Visual Pathway Diseases....................Laurel Vuong, MD
2:50 VEP and ERG in Neuro-ophthalmology...............Nurhan Torun, MD
3:05 Visual Fields for Neuro-ophthalmology Diagnosis and Management.........................Geetha Athappilly, MD
3:20 Panel Discussion ..................................Thomas Hedges, MD, Moderator  
Geetha Athappilly, MD  
Marc Bouffard, MD  
Bart Chwalisz, MD  
Crandall Peeler, MD  
Joseph Rizzo, MD  
Nurhan Torun, MD

4:00 Adjourn
AFTERNOON SUBSPECIALTY SESSION  FREEDOM ROOM  
(Lower Level)

UVEITIC MASQUERADES

Moderator: Nicholas Butler, MD  
Program Committee Coordinator: Michael Yoon, MD

Professional Practice Gaps: Using feedback from NEOS members and Program committee, identified the following professional practice gaps: 1) Non-neoplastic and neoplastic masquerades in uveitis; 2) Identifying signs and symptoms suggestive of a uveitic masquerade, which may help the clinician to differentiate the presentation from that of true ocular inflammatory disease.

NEOS Program Objectives:
The content and format of this education activity has been specifically designed to fill the practice gaps in the audience's current and potential scope of professional activities by:

1. Providing an overview of the various non-neoplastic uveitic masquerades, such as retinitis pigmentosa (especially sine pigmenti variant), pigment dispersion syndrome, ocular ischemic syndrome, ocular amyloid, among others, with particular attention to the various signs and symptoms that may help to differentiate these diseases from uveitis.

2. Updating the audiences’ understanding of the various presentations of and diagnostic approach to lymphomatous disease of the eye, focusing on primary intraocular lymphoma while also addressing primary uveal lymphoma and systemic lymphoma.

3. Reviewing additional neoplastic masquerades, including other hematologic malignancies such as leukemias and multiple myeloma, as well as solid tumors in both the adult and pediatric populations.

1:00 pm  Introduction of Session .......................... Nicholas Butler, MD
1:05   Introduction of the Uveitic Masquerades .............. Ninani Emang Kombo, MD
1:20  Primary Intraocular Lymphoma ........................... C. Stephen Foster, MD
1:35  Non-CNS Ocular Lymphoma: Primary Uveal Lymphoma and Systemic Lymphoma ............................ Lucia Sobrin, MD
1:50  Other Hematologic, Neoplastic Masquerades ................ Robert Janigian, MD
2:05  Solid Tumor Masquerades in Adults .......................... Jay Duker, MD
2:20  Juvenile Neoplastic Masquerades ........................... Ankoor Shah, MD
2:35  Refreshment Break/Exhibits
3:05  Panel: Mystery Case Presentations of  
     Uveitic Masquerades ........................................... Nicholas Butler, MD, Moderator
     Jay Duker, MD  Ninani Emang Kombo, MD  
     C. Stephen Foster, MD  Ankoor Shah, MD  
     Robert Janigian, MD  Lucia Sobrin, MD
4:00  Adjourn
THE LATEST IN CORNEAL SURGERY:
CLIMBING THE STEEP LEARNING CURVE

Joseph M. Williams, MD, PhD
WORCESTER, MA

Objective: To discuss emerging cornea procedures and identify complications associated with these procedures

The last 25 years has seen both a revolution and evolution of corneal surgery encompassing both corneal modification procedures and corneal replacement procedures. When compared to the last 100 years this has occurred at a head spinning pace and has resulted in a virtual alphabet soup of abbreviations to describe these new surgical procedures: PRK, LASIK, LASEK, SMILE, cornea CXL, epi on CXL, epi-off CXL, intrastromal rings/segments, PKP, ALK, ALTK, DALK, DLEK, DSEK, DSAEK, UT-DSAEK, NT-DSAEK, PDEK, DMEK, DSET, DWEK, DSO. The common thread to the evolution of these procedures is standardization of the techniques and minimizing operative and post-operative complications. Complications may occur intra-operatively or post-operatively and can be broadly grouped as mechanical, inflammatory, and infectious. Complications specific to these evolving procedures that will be addressed include: pupillary block; graft preparation, unfolding, orientation; graft adherence/dislocation; Descemets perforation in DALK; post-operative complications of interface infections; increased incidence of fungal infections. There are excellent resources on the internet that allow an incredible amount of self-education, discussion, and online debate of these revolutionary and evolutionary techniques with complete surgical videos. While these resources are not peer reviewed they are real time and more current than any print journal. It is up to each individual ophthalmologist to determine and evaluate the validity of these sources. The internet blog “kera-net” offers some of the best current information on these evolving corneal surgical procedures.

References: “Kera-net” --- May be joined through the Cornea Society website
Moloney MD, Greg DWEK/DSO: https://www.youtube.com/watch?v=E7qhbsfx_yY
Davies E, Jurkunas U, Pineda II, R. Predictive Factors for Corneal Clea
NEW REFRACTIVE FRONTIERS:
FACING THE UNEXPECTED

Jason Brenner, MD
Boston Eye Group
BROOKLINE, MA

Objective: To review complications of emerging refractive procedures that may be routinely encountered and how to address them.

A case based series of refractive complications will be presented with corneal and ocular imaging as well as surgical video when appropriate. Topics discussed will include corneal haze after presbyopia correcting corneal inlays (Raindrop and Kamra), cataract surgery in the setting of corneal inlays and phakic intraocular lenses (Visian ICL), intraoperative LASIK flap creation issues with the femtosecond laser and enhancement options after small incision lenticule extraction (SMILE).

Siedlecki J et al. Enhancement after Myopic SMILE using Surface Ablation. JRS 33(8)
EMERGING GLAUCOMA SURGERY:
LOWER IOP WITHOUT RAISING THE RISK

Susan Liang, MD
Tufts Medical Center
BOSTON, MA

Objective: To review complications associated with the most current Micro-Invasive Glaucoma Surgeries and their management.

In today’s glaucoma treatment paradigm, tube shunts and trabeculectomy continue to be most efficacious in lowering eye pressure. According to the TVT studies, the 5-year average IOP for tube and trabeculectomy was 14.4 mmHg and 12.6 mm Hg respectively. Although highly effective, both surgeries carry similar rates of dreaded and potentially vision-threatening complications, like blebitis, endophthalmitis, hypotony maculopathy, and choroidal hemorrhage. Micro-invasive glaucoma surgery (MIGS) has emerged to provide safer, and less invasive surgical treatment options with modest efficacy. This presentation will review the safety profile of the most current MIGS that target increasing trabecular, suprachoroidal, and subconjunctival flow, and discuss strategies to manage complications as these new surgeries are implemented in daily practice.


Various sticky situations are there in cataract surgery in which implanting an IOL is difficult. In such cases the Glued IOL works well and can restore vision to the patient. In this two scleral flaps are created 180 degrees apart and the three piece PC IOL haptics externalised through the sclerotomies and tucked into intrascleral pockets and the. Glued down using fibrin glue. Marfans syndrome, traumatic cases. PC ruptures all can benefit from this procedure.
Objective: To identify and initiate management of complications from novel oculoplastic surgeries.

Novel procedures in the field of ophthalmic plastic surgery tend to fall in one of a few categories: (1) the application of new materials, (2) alternate anatomic approaches to address pathology, and (3) use of new technology or instruments. Due to the high success rates of standard oculoplastic techniques, the adoption of novel procedures in oculoplastic surgery may lag behind other ophthalmic specialties. Complications from these newer procedures are relatively rare and procedure-specific, published as case reports or presented at specialty-specific meetings. In this discussion, we will review different types of complications that arise from novel oculoplastic techniques, including adverse reactions to implanted materials, migration of implants, hemorrhage and infection, malposition of the lids or globe, and failure to correct the underlying problem. We will also address diagnosis and management options from the general ophthalmologist’s perspective.


WHAT’S EMERGING BEHIND THE LENS:
NEW RETINA PROCEDURES AND ASSOCIATED PITFALLS

Archana Seethala, MD
Boston University Medical Center
BOSTON, MA

Objective: To highlight cutting edge advancements in the field of vitreoretinal surgery as well as their associated risks and complications.

We have seen incredible progress in the field of vitreoretinal disease over the last few decades including but not limited to - intravitreal injections, OCT/ OCT angiography, and small (27) gauge vitrectomy - which have all changed the scope of how we approach and treat retinal disease. These innovations continue to improve the way we practice, as well provide further options for our patients.

During this presentation we will discuss several of these developments including sutureless scleral fixated IOL’s, Argus II retinal implants, stem cell / gene therapy for dry macular degeneration and hereditary retinal dystrophies. We will also briefly introduce advanced 3D surgical imaging.

While promising, all of these advancements do have their own respective limitations, complications and concerns.

References: Humayun MS et al. A bioengineered retinal pigment epitheial monolayer for advanced dry age related macular degeneration. Sci Transl Med. 2018 Apr 4;10(435)
CORNEAL TRANSPLANTATION WITH PRE-DESCEMETS ENDOTHELIAL KERATOPLASTY AND SINGLE PASS 4 THROW PUPILLOPLASTY: BOLD AND BEAUTIFUL

Amar Agarwal, MS, FRCS, FRCOphth
CHENNAI, INDIA

PDEK implants the endothelium Descemets membrane and the pre Descemets later. This is about 25 micron. The biggest advantage is that this can be prepared from any donor age. It has the advantages of both DSEK and DMEK without their disadvantages. Single pass 4 throw pupilloplasty helps open the closed angle glaucoma cases and also helps in cases of bad pseudo phakic bullous keratopathy. This is a simple procedure which can be easily replicated.
Residents and fellows from all the New England ophthalmologic teaching programs have submitted abstracts for our annual scientific poster presentation contest being conducted today. Posters will be judged on originality and scientific merit. Awards will be made for the first prize $500.00, second prize $300.00, third prize $200.00 and three honorable mentions of $50.00 each. Funding for the awards is derived from a gift to the NEOS Education Endowment Fund honoring the late Sanford Hecht, MD.

Please take some time to stop by these interesting posters in the lower lobby.

NEOS thanks Donna Siracuse-Lee, MD, the Moderator of the Poster Contest, and this year’s judges, Crandall Peeler, MD, Veena Mathew, MD and Angela Turalba, MD
DOXORUBICIN (DXR) & HIF-1 INHIBITOR (HIF-1I) POLYMER CONJUGATES IN CHOROIDAL (CNV) AND RETINAL NEOVASCULARIZATION (RNV) MODELS

Rishi Chadha, BS
Frank H. Netter School of Medicine at Quinnipiac University
HAMDEN, CT

Objective: To determine the efficacy of novel therapeutics for the treatment of retinal and choroidal neovascularization.

Ocular neovascularization is a huge cause of vision loss in individuals throughout the world. The two main types are retinal (RNV) and choroidal neovascularization (CNV). RNV occurs in ischemic retinopathies such as diabetic retinopathy, the most common cause of moderate to severe vision loss in working class Americans. CNV occurs in diseases such as age related macular degeneration (AMD) and is the leading cause of vision loss in people ages 50 and over. While there are treatments, many have limited efficacy thus requiring consistent treatment which can lead to reduced patient compliance. Doxorubicin (DXR) and HIF-1 Inhibitor (HIF-1I) targets HIF-1, a master regulator of angiogenesis. This study will evaluate whether DXR and HIF-1I are effective treatment options for RNV and CNV. We used CNV and oxygen-induced retinopathy (ROP) generated mice models and conducted intraocular injections of both the DXR and HIF-1I particles as well as controls. Flat mounts of the choroid and retina were taken and neovascularization was measured using fluorescence microscopy and image analysis. Intraocular injection of 1µg of HIF-1I in the ROP mice model resulted in a 37% in NV while the injection of 1µg of DXR2 resulted in a 28% reduction. Intraocular injection of 1µg of HIF-1I immediately after rupture of Bruch’s membrane resulted in a 44% reduction in CNV while the injection of 1µg of DXR2 resulted in a 38% reduction. Both of these particles showed significant reduction in neovascularization in both CNV and ROP model mice. Future studies may include attempting suprachoroidal injections in rat CNV models. Suprachoroidal injections as this would allow the drug to be in a location where it is needed as well as reduce the risk of many complications such as vitreous hemorrhage, retinal detachment and floaters.
Role of OCT in Monitoring for Ethambutol Induced Optic Neuropathy

Sona Chaudhry, MD
Boston Medical Center
BOSTON, MA

Objective: To assess the utility of ocular coherence tomography (OCT) in detecting subclinical ethambutol-induced optic neuropathy.

Introduction: Toxic optic neuropathy is a rare but serious complication of ethambutol use. The incidence of optic neuropathy increases with sustained periods of the drug’s standard loading dose (25 mg/kg/day). To date, there are no known strategies for detecting subclinical ethambutol-induced toxicity, which if detected early may be reversed upon stopping the drug. We assess the utility of ocular coherence tomography (OCT) in detecting subclinical ethambutol-induced optic neuropathy.

Methods: We present a prospective case series of seven patients started on ethambutol and referred to the ophthalmology clinic for monthly screening while on the medication. Visual acuity, color vision, automated perimetry, and OCT of the optic nerve head with retinal nerve fiber layer (RNFL) analysis were obtained and analyzed. Progression analysis from the Heidelberg OCT was utilized to track the RNFL thickness over time. Statistical significance was defined as a p-value <0.05.

Results: All seven patients had a baseline BCVA of 20/20, full color vision, and normal RNFL thickness on OCT. All but one patient had full baseline visual field testing. Ethambutol doses ranged from 12.5mg/kg/day to 26.0mg/kg/day. Mean follow up was 5.6 months from initial screening (Range 1-12 months). No patients in the cohort developed afferent visual dysfunction but three of seven cases showed an upward trend in RNFL thickness, although not statistically significant (p-value 0.57 to 1.0).

Conclusion: We demonstrate an upward trend in RNFL thickness in patients following initiation of ethambutol therapy. We hypothesize that this thickening results from subclinical optic nerve toxicity, manifest as subtle axonal swelling that may precede the development of frank optic atrophy. Larger studies are required to determine whether a “threshold” value of thickening exists that is associated with clinical changes in afferent visual function.
THE EFFECT OF EPIRETINAL MEMBRANE ON DRUSEN VOLUME AS QUANTIFIED BY SD-OCT

Emily Li, MD
Yale University
NEW HAVEN, CT

Objective: To quantitatively investigate the relationship between presence of ERM and macular drusen volume in patients with non-exudative AMD.

Background: Macular drusen is a characteristic feature of age-related macular degeneration (AMD), a common disease affecting one in ten adults 75 years and older. The pathophysiology behind drusen accumulation remains uncertain, and there is no known treatment to decrease drusen load, though there have been reports of spontaneous drusen resorption and drusen regression after laser photocoagulation, rhegmatogenous retinal detachment, intravitreal anti-vascular endothelial growth factor injection, and vitrectomy with internal limiting membrane peeling. Select cases from our clinical context suggest there may be an unexplored relationship between the macular drusen present in non-exudative AMD and epiretinal membranes (ERM).

Objective: We aimed to quantitatively investigate the relationship between presence of ERM and macular drusen volume in patients with non-exudative AMD.

Methods: We retrospectively searched records from January 1, 2007 to December 31, 2016 to identify patients who have concurrent diagnoses of macular drusen or non-exudative AMD and ERM using ICD-9 and ICD-10 billing codes. Exclusion criteria included age under 18 years and history of trauma, intravitreal injection, exudative AMD, retinal laser photocoagulation, vitreoretinal surgery, and diabetes mellitus. Of the 163 patients identified, 8 met the inclusion criteria of having macular drusen in both eyes and ERM in one eye, as well as available Heidelberg spectral domain optical coherence tomography (SD-OCT) imaging. Our primary outcome was macular drusen volume in a 6 mm-diameter macular area on SD-OCT, obtained using Heidelberg segmentation software. We derived the drusen volume between Bruch’s membrane (BM) and the retinal pigment epithelium (RPE) by first removing automated segmentation of each retinal layer. We manually outlined BM and the RPE such that there was space between the two lines only when drusen was present and obtained volume through Heidelberg segmentation software. Two investigators independently performed this task and average volumes between the two data sets were used in analysis. The Yale University Institutional Review Board approved this study.

Result: The averaged drusen volume was higher in the eye without an ERM compared to the ERM eye in eight out of eight patients. The eyes without an ERM had a mean drusen volume of 0.256 mm³ [+/− 0.153 mm³] while the fellow eyes with an ERM had a mean drusen volume of 0.188 mm³ [+/− 0.063 mm³]. A two-tailed paired t-statistic test yielded a p-value of 0.150.
**Conclusion:** Our cohort of non-exudative AMD patients with concurrent bilateral macular drusen and unilateral ERM had lower drusen volumes in the ERM eye compared to the fellow eye, as measured by manual segmentation on Heidelberg SD-OCT. Although this difference was not statistically significant in our sample, all eight patients conformed to this trend. Findings warrant further investigation in the relationship between ERM and drusen accumulation with a larger study size. Elucidating a better understanding of macular drusen deposits, a finding present in various vision-threatening diseases including AMD, may benefit global comprehension of their pathophysiology and the driving forces behind the disease processes in which they manifest.

**References:**


OPTIMIZATION OF THE DIAGNOSIS AND MANAGEMENT OF RETROBULBAR HEMORRHAGES IN THE ADULT EMERGENCY ROOM SETTING: A RESIDENTS-EDUCATING-RESIDENTS INITIATIVE

Emily Li, MD
Yale University
NEW HAVEN, CT

Objective: To investigate the effect of implementing a formalized resident-teaching-residents curriculum on the preparation of emergency department residents.

Background: Retrobulbar hemorrhages are one of the most serious ophthalmological emergencies often presenting first to the emergency room setting. Prompt diagnosis and rapid intervention—lateral canthotomy and cantholysis—are crucial to visual prognosis. Given this urgency, it is fundamental to optimize the efficiency and efficacy of recognition and intervention. In the Yale-New Haven Hospital (YNHH) Adult Emergency Department (ED), emergency room providers are almost always the first responders to patients with retrobulbar hemorrhages, followed subsequently by ophthalmology residents. It is unknown whether a formalized curriculum for emergency medicine residents would enhance the preparation of providers to recognize and treat patients with retrobulbar hemorrhages presenting to the YNHH Adult ED.

Methods: We conducted a prospective interventional study to investigate the effect of implementing a formalized resident-teaching-residents curriculum on the preparation of emergency department residents. Our intervention consisted of a 45-minute lecture designed to educate emergency medicine residents on the recognition and treatment of retrobulbar hemorrhages. Our primary outcome measure was the difference in scores from a one-paged written assessment given prior to and after the intervention. The evaluation consisted of five prompts that measured subjective comfort level and objective knowledge base. We asked each resident to disclose their post-graduate year (PGY) and the number of lateral canthotomy and cantholysis procedures they performed prior to our intervention. We used paired t-test to compare scores from before and after our intervention and analysis of variance (ANOVA) to compare scores among the PGY cohorts. We used a two-tailed p-value cutoff of <0.1 to indicate statistical significance.

Result: A total of 21 emergency department residents—six PGY-1, seven PGY-2, two PGY-3, and seven PGY-4—were included in the study. Of these, two residents indicated they each have performed one lateral canthotomy and cantholysis procedure before the study intervention. The mean score was 1.86 prior to intervention and 3.55 after intervention (p <0.0001). We did not perform subgroup analysis within each PGY cohort given their lower n-values do not provide enough statistical power. There was no statistically significant difference in scores among the three PGY cohorts (p = 0.64).
**Conclusion:** Retrobulbar hemorrhages are sight-threatening emergencies that require prompt recognition and management through the performance of a lateral canthotomy and canthoysis to prevent permanent vision loss. We implemented a peer education initiative that significantly improved the preparation of YNHH emergency medicine residents to be able to provide appropriate care for patients with retrobulbar hemorrhages in the YNHH ED.
ENDOCYCLOPHOTOCOAGULATION OUTCOMES
FOR DIFFERENT GLAUCOMA TYPES AND STAGES

Michael Lin, MD
Massachusetts Eye and Ear Infirmary
BOSTON, MA

Objective: To evaluate endocyclophotocoagulation outcomes for different glaucoma types and stages.

Purpose/Relevance: Minimally invasive glaucoma surgery has traditionally been thought to be less effective for more advanced stages of glaucoma. Endocyclophotocoagulation shrinks ciliary processes and is thought to decrease intraocular pressure (IOP) by opening the drainage angle and reducing aqueous production. Therefore, this study seeks to determine whether angle configuration and glaucoma disease staging affect ECP outcomes for reduction of both IOP and glaucoma medications.

Methods: Retrospective chart review of eyes that underwent ECP, with or without concurrent cataract extraction, between October 2010 and December 2016 at one institution. Exclusion criteria included not having follow-up at 1 year after surgery. Based on the Hodapp-Parrish-Anderson staging system, patients were divided into mild, moderate, and advanced glaucoma. Outcome measures were degree of IOP reduction and change in number of glaucoma medications.

Results: There were 118 eyes of 97 patients that had at least 1 year of follow-up. Of these, 105 had concurrent cataract extraction. Eyes undergoing standalone ECP had greater IOP reduction than eyes undergoing ECP with concurrent phacoemulsification, but not greater medication reduction (9.1 vs 2.9 mmHg, p=0.001; 0.9 vs 0.6 medications, p=0.36). Glaucoma severity was mild in 39 eyes, moderate in 34, and advanced in 26. At 1 year, there was no difference in IOP reduction or medication reduction for eyes with mild, moderate, or advanced glaucoma (decrease of 3.0, 3.4, and 2.0 mmHg, respectively, p=0.56; decrease of 0.5, 0.8, and 0.7 medications, respectively, p=0.49). Greater preoperative IOP was directly correlated with greater IOP reduction (R²=0.69). The 30 eyes with chronic angle closure glaucoma (CACG) had greater IOP reduction and medication reduction than the 55 eyes with open angle glaucoma (5.5 vs 1.9 mmHg, p=0.01; 1.1 vs 0.2 medications, p=0.0001).

Discussion: In this study, eyes with CACG were more responsive to ECP than eyes with other types of glaucoma. Stage of glaucoma was not associated with degree of IOP reduction or medication reduction after ECP.

Conclusion: ECP can reduce IOP and medication use, particularly in CACG, and it can be employed for all stages of glaucoma.

**DIRECT-TO-CONSUMER VIRTUAL VISITS: FEASIBILITY OF A NEXT-GENERATION HEALTH CARE DELIVERY SYSTEM IN OPHTHALMOLOGY**

*Marissa Lynn, BA*
*Harvard Medical School*
*ROXBURY CROSSING, MA*

**Objective:** To evaluate the feasibility and economics of direct-to-consumer virtual visits (VVs) connecting patients to clinicians on a secure video platform allowing access to care from any location.

**Methods:** Retrospective review of ophthalmology VVs conducted at Boston Children’s Hospital on a custom-designed, device-agnostic, secure video platform. Primary outcome was provider-defined visit efficacy as measured by provider-facing surveys. Secondary outcomes were provider and patient metrics obtained via surveys and comprehensive chart review. Cost savings were calculated with a subset of assumptions for economic modeling of clinical business development used across BCH.

**Results:** In 13 months, 3 providers conducted 57 VVs with 91% of encounters rated as effective. Patient satisfaction was 90% overall with benefits of convenience (100%), efficiency (82%), and improved access (73%). Providers saw post-operative (26), return (26), and new (5) visits with 37 strabismus, 7 orbital, and 13 ocular surface diagnoses. No negative outcomes were encountered. In comparison to the consumer expense of in-person visits, VVs saved patients ~$18,686 and >179 hours of travel and wait time.

**Conclusions:** VVs can provide high patient/provider satisfaction. While there were no negative outcomes, prospective comparisons will be required to evaluate quality and safety. Additionally, VVs offered significant time and cost savings for patients. Provider-sided economics does need to be estimated next to understand if there is similar savings before the economics of VVs is fully understood.

**References:**

OUTCOMES IN RESIDENT-PERFORMED CATARACT SURGERIES WITH IRIS CHALLENGES: RESULTS FROM THE PCIOL STUDY

Giannis Moustafa, MD

BOSTON, MA

Objective: A study on surgical education attempting to examine the outcomes of resident and attending surgeons when operating on eyes with iris challenges, and compare between them.

Purpose: To assess the outcomes of resident-performed cataract surgeries with iris challenges and to compare these outcomes to similar surgeries performed by attending physicians.

Setting: Massachusetts Eye and Ear Infirmary, Harvard Medical School.

Design: Retrospective chart review.

Methods: All cases of cataract extraction by phacoemulsification with intraocular lens insertion performed by comprehensive ophthalmologists between January 1 and December 31, 2014, were reviewed, and cases with pre- or intraoperative miosis, iris prolapse, and floppy iris syndrome (IFIS), were included. Visual outcomes and the rate of perioperative untoward events were compared for resident and attending cases. Factors predicting untoward events were also assessed.

Results: In total, 1931 eye cases of 1434 patients were reviewed, and 65 resident and 168 attending cases were included. Mean logMAR best-corrected visual acuity was better in the resident group one month after surgery (0.051±0.10 versus 0.132±0.30, p=0.03), but the difference was eliminated when controlling for macular disease. Mean operative time was 43.8±26.5 and 30.9±12.6 minutes for cases performed by resident and attending surgeons, respectively (p<0.0001). Residents utilized supplemental pharmacologic dilation or retraction more frequently than attendings (98% versus 87% of cases, p=0.008). The overall rate of untoward events was no different between residents and attendings (p=0.16). Dense nuclear sclerosis predicted untoward events in cataract cases with iris challenges (adjusted odds ratio=1.86, p=0.001, 95% confidence interval 1.17-2.94).

Conclusion: Although requiring a longer operative time and more surgical manipulation, resident-performed cataract surgeries with iris challenges achieve outcomes comparable to those performed by attending surgeons, and residents should be given the opportunity to operate on these cases.

GELATIN-BASED HYDROGEL AS A VEHICLE FOR RETINAL PROGENITOR CELL TRANSPLANTATION

Jeayoung Park, BS
Yale University
NEW HAVEN, CT

Objective: Evaluation of in vitro biocompatibility and in vivo transplant survival of retinal progenitor cell grafts using injectable polymer materials as a cell delivery method inside rats.

One of the current limitations of retinal transplantation of stem cells as well as other cell types is loss of cells and low graft survival. Gelatin-Hydroxyphenylpropionic acid (Gtn-HPA) is a biodegradable hydrogel that can undergo gelainization in vivo, which can preserve injected cells. We tested the hypothesis that Gtn-HPA hydrogel supports survival and integration of RPC transplantation. In vitro biocompatibility of Gtn-HPA with human RPCs (hRPCs) as well as in vivo survival of xenografted GFP+ pig RPCs (pRPCs) in rats were characterized with immunocyto/histochemistry. hRPCs showed equivalent % viability when cultured in a thin layer of Gtn-HPA compared to fibronectin-coated cover slides (control group). Caspase-3 Staining showed minimal apoptotic cells by day 4, and Ki-67 staining demonstrated proliferating cells in all days in culture. Transplanted pRPCs were found in tighter clusters in the subretinal space when injected with Gtn-HPA compared to saline control. GFP+ cell population was roughly equivalent in numbers between the hydrogel and liquid vehicle groups. Subretinal grafts showed no visible immune cell infiltration when stained with CD45. Gtn-HPA shows promise as an injectable and biodegradable polymer vehicle for subretinal stem cell transplantation.
REGIONAL VESSEL CALIBER, RETINAL OXIMETRY AND PREDOMINANTLY PERIPHERAL DIABETIC RETINAL LESIONS AS SURROGATE MARKERS OF NONPERFUSION ON ULTRAWIDE FIELD ANGIOGRAPHY IN DIABETIC EYES

Alex Pisig, MD
Joslin Diabetes Center
ROSLINDALE, MA

Objective: To evaluate whether predominantly peripheral lesions (PPL), regional differences in retinal vessel diameters and oximetry changes are associated with the extent of retinal nonperfusion (NP) on ultrawide field fluorescein angiography in diabetic eyes.

Methods: Vessel diameters, ETDRS diabetic retinopathy (DR) severity and presence of PPL were evaluated on UWF 200-degree images. Retinal oximetry and UWF-FA were obtained at the same visit. Vessel calibers at 1-disc diameter (DD, inner-AVR) and 3.5 DD (outer-AVR) from the center of the disc were measured using a customized semiautomated computer program. Retinal NP (mm2) was measured from UWF-FA images. Venous oxygen saturation (VO2, %) and arteriovenous difference (A-V, %) were calculated within a 2 DD ring centered on the optic disc.

Results: A total of 39 eyes from 20 subjects with mean age 40.7±10.7 yrs, diabetes duration 21.1±10.4 yrs, HbA1c 7.7%±1.1, 65.0% male and 75.0% type 1 diabetes were evaluated. DR severity was no DR 10.3%(4 eyes), mild nonproliferative DR (NPDR) 48.7%(19), moderate 20.5%(8), severe 10.3%(4), and proliferative DR 10.3%(4). PPL were present in 56.4%(22) of eyes and associated with increasing DR severity (p=0.006) as well as increasing NP & VO2, and decreasing A-V. In all eyes, NP was associated with increasing DR severity (r=0.60, p<0.0001) and increasing outer venular diameters (r=0.45, p=0.0370). In eyes without PPL (N=17), NP was correlated with increasing inner (r=0.45, p=0.0370) and outer (r=0.68, p=0.0021) venular diameters. Correlation between inner and outer AVR was present only in eyes with no PPL (r=0.50, p=0.03) suggesting differences between inner and outer zones in eyes with PPL (r=0.29, p=0.18).

Conclusions: In this cohort, increasing NP was associated with increasing DR severity, venular dilation, increased VO2 and decreased A-V, suggesting greater areas of retinal ischemia, presence of venous shunting and reduced retinal oxygen utility. In eyes with PPL, regional differences in vessel caliber were correlated with increasing peripheral NP and provide further evidence that the risk of progression with PPL is driven by retinal ischemia.
Objective: To identify diabetic MA wall characteristics on adaptive optics scanning laser ophthalmoscopy as well as blood flow parameters estimated by computational fluid dynamics modeling that are correlated with OCTA MA visibility.

Purpose: OCTA does not successfully image all MAs, yet it is unclear what determines MA OCTA visibility. Our goal was to identify diabetic MA wall characteristics on adaptive optics scanning laser ophthalmoscopy (AOSLO) as well as blood flow parameters estimated by computational fluid dynamics (CFD) modeling that are correlated with OCTA MA visibility.

Methods: Retinal MAs in diabetic eyes were imaged by AOSLO and OCTA (Optovue, software ver 2017.1.0.149) at the same visit. AOSLO images were graded for wall hyperreflectivity (WH), wall deformability (WD), cross-sectional area, clot presence, perfusion percentage and morphology. On OCTA, MAs were assessed as fully visible (FullVis), partially visible (PartVis) or not visible (NoVis). Multimodal images for each MA were registered. CFD modeling estimated shear rate drop (SRD) and wall shear stress drop (WSSD) within a subset of MAs. Statistical analyses adjusted for correlations between follow-up images of individual MAs.

Results: A total of 162 MAs (45 eyes) were imaged (259 sessions, 97 MAs with >1 follow-up). On OCTA, MAs were 58.7% (N=152) FullVis, 21.2% (55) PartVis and 20.1% (52) NoVis. FullVis MAs had greater perfusion percentage (FullVis mean±SD: 71.4±29.9%, PartVis: 52.8±32.3% NoVis: 41.5±36.4%, p<0.0001).

Conclusion: In this study, over 40% of MAs present on AOSLO were not fully visible in superficial or deep capillary plexus OCTA images. OCTA visibility appeared to be more dependent on MA perfusion than size. Thus, OCTA evaluation of MA may particularly underestimate MAs with limited perfusion. Computational modeling may help identify MAs with slower blood flow that may be less visible on OCTA. These data support future investigations to determine the implications of MA OCTA visibility for predicting local neural retinal pathology and visual dysfunction in the diabetic eye.
EFFICACY OF GONIOSURGERY FOR NEWBORN VERSUS INFANTILE PRIMARY CONGENITAL GLAUCOMA

Helen Yeung, MD
Massachusetts Eye and Ear Infirmary
BOSTON, MA

Objective: To report the surgical results of goniosurgery (goniotomy or trabeculotomy) for newborn and infantile primary congenital glaucoma (PCG).

This is a retrospective review of patient records with newborn PCG and infantile PCG who underwent initial goniosurgery. Newborn PCG were those children with PCG diagnosed within the first 1 month of age and infantile PCG were those children with PCG diagnosed later, between 1 and 13 months of life. Complete success was defined as intraocular pressure (IOP) less than 23, qualified success as IOP less than 23 with medications, and failure as IOP greater than 23 requiring other types of glaucoma surgery.

For the newborn PCG group, there was a total of 38 patients with 72 eyes. 92% (66 of 72 eyes) failed in controlling IOP after goniosurgery while 8% (6 of 72 eyes) achieved either qualified or complete success. The interval of goniosurgery to failure was 0.75 years (range: 3 days – 11 years). For the infantile PCG group, there were a total of 142 patients with 220 eyes. 97% (213 of 220 eyes) achieved complete success in controlling IOP while 3% (7 of 220 eyes) failed. The average postoperative interval follow-up was 10.5 years (range: 8 months – 40 years).

Careful gonioscopy and inspection of the irides are imperative to determine the correct PCG diagnosis and the severity of the related filtration angle anomalies in order to select the appropriate surgical technique to perform for the proper subtype of PCG. Goniosurgery is not successful in all forms of PCG. It is highly successful in controlling IOP in the infantile PCG group compared to newborn PCG. Therefore, these results and the correct diagnosis of children with PCG are important in determining the appropriate glaucoma surgery for these young patients.

As a provider accredited by the Massachusetts Medical Society, NEOS must ensure balance, independence, objectivity, and scientific rigor in all its individually and jointly provided educational activities. All individuals in a position/role to control the content of an activity are expected to disclose to NEOS any relevant financial relationships they and their spouse/partner have with commercial interests.

The ACCME defines a commercial interest as any entity producing, marketing, reselling or distributing health care goods or services consumed by, or used on, patients. Relevant financial relationships are financial relationships in any amount, which occurred in the twelve-month period preceding the time that the individual was asked to assume a role controlling content of the CME activity, and which relate to the content of the educational activity.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as independent contractor (including contracted research), consulting, promotional speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. The MMS/ACCME considers relationships of the person involved in the CME activity to also include financial relationships of a spouse or partner.

Amar Agarwal:
- **Royalty**: Thieme Slack Incorp Mastel
- **Consulting Fees**: Staar Surgicals
- **Grant Support**: Bausch & Lomb

Bradbury, Michael:
- **Ownership Interest**: Regeneron, Chase and Associates, Inc (Iviews imaging system)

Dagianis, John:
- **Fees for Non-CME Services Received Directly from Commercial Interest or their Agents**: Luminus, Speaker Bureau

Duker, Jay:
- **Consulting Fees**: Allergan, Santen, Aura, Biosciences, Ironwood Pharma, Bayer, Novartis, Thrombogenics, Tyrogenis
- **Contracted Research**: Carl Zeiss Meditec, Optovue, Topcon
- **Ownership Interest**: Hemera, Biosciences
- **Other types**: Elevan Biotherapeutics (Board of Directors), pSivida Corp (Board of Directors)
Foster, C. Stephen:  
**Consulting Fees**: Aldeyra Therapeutics, Bausch & Lomb Surgical, Eyegate Pharma, pSivida, Xoma  
**Fees for non-CME services**: Payment for lectures and speaking bureaus – Alcon, Allergan  
**Ownership Interest**: Eyegate Pharma  
**Other**: Grants: Alcon, Aldeyra Therapeutics, B&L, Clearside Biomedical, Dompe Pharma, Eyegate Pharma, Novartis, Mallinckrodt pharmaceuticals, pSivida, Santen

Heier, Jeffrey:  
**Consulting Fees**: 4D Molecular Technologies, Adverum, Aerie, Aerpio, Allegro, Apellis, Asclepix, Bayer, BVI, Coda Therapeutics, Corcept, Daiichi-Sankyo, Genentech/Roche, Heidelberg, Hemera, Janssen R&D, Kanghong, Kodiak, Neurotech, Notal Vision, Novartis, Ocular Therapeutix, Quark, Ra Pharmaceuticals, Regeneron, Regenxbio, Scifluor, Shire, Stealth Biotherapeutics, Thrombogenics, TLC, Tyrogenex  
**Contracted Research**: Aerpio, Apellis, Astellas, Corcept, Daiichi Sankyo, Genentech/Roche, Genzyme, Hemera, Janssen R&D, Ophthotech, Optovue, Regeneron, Regenxbio, Scifluor, TLC, Tyrogenex  
**Ownership Interest**: Ocular Therapeutix, Adverum

Noecker, Robert  
**Consulting Fees**: Allergan, Alcon, Inotek, Aerie, Ocular Therapeutics, Kateena, BVI, Iridex, Quantel, Santen, Glaukos, Shire, Sun, Polyactiva, Diopsys, Ethis Communications, SOLX  
**Fees for Non-CME Services Received Directly from Commercial Interest or their Agents** - Allergan, Alcon, Inotek, Aerie, Ocular Therapeutics, Kateena, BVI, Iridex, Santen, Iridex, Glaukos, Diopsys  
**Contracted Research**: Allergan, Glaukos, Santen  
**Ownership Interest**: Ocular Therapeutics

Rizzo, Joseph:  
**Receipt of Intellectual Property Rights/Patent Holder**: Bionic Eye Technologies  
**Consulting Fees**: GenSight  
**Ownership Interest**: Bionic Eye Technologies

**NO FINANCIAL INTEREST**

None of the other individuals in a position to control the content of this activity, including planners, CME Review Committee members, faculty presenters, moderators, panelists and reviewers have any relevant financial relationship with an ACCME-defined commercial interest to disclose.
CANDIDATES FOR MEMBERSHIP

The following candidates have submitted application for membership and letters of support have been received by sponsors:

<table>
<thead>
<tr>
<th>Candidate</th>
<th>Sponsor</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kara LaMattina, MD</td>
<td>Manju Subramanian, MD</td>
<td>Stephen Christiansen, MD</td>
</tr>
<tr>
<td>Boston, MA</td>
<td>Boston, MA</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Robert Millay, MD</td>
<td>Christopher Brady, MD</td>
<td>Phil Aitken, MD</td>
</tr>
<tr>
<td>Burlington, VT</td>
<td>Burlington, VT</td>
<td>Burlington, VT</td>
</tr>
</tbody>
</table>

REMINDER that new member candidates should apply ONLINE

FUTURE NEOS MEETINGS

<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>September 28</td>
<td>Cataract (with Pender Lecture)</td>
<td>Susannah Rowe, MD</td>
</tr>
<tr>
<td>(HYNES)</td>
<td>Ethics and Risk Management</td>
<td>Christopher Soares, MD</td>
</tr>
<tr>
<td>November 30</td>
<td>Neuro-ophthalmology and Plastics</td>
<td>Michael Yoon, MD</td>
</tr>
<tr>
<td></td>
<td>Posterior Segment Case Presentations</td>
<td>Jay Duker, MD, Joan Miller, MD</td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>March 1</td>
<td>Cornea</td>
<td>Adam Sise, MD</td>
</tr>
<tr>
<td></td>
<td>Subspeciality Day: Pediatrics</td>
<td>Iason Mantagos, MD</td>
</tr>
<tr>
<td></td>
<td>Refractive Refractive Refractive Imaging</td>
<td>Kathryn Hatch, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nadia Waheed, MD</td>
</tr>
<tr>
<td>April 12</td>
<td>Anterior Segment Case Presentations</td>
<td>Michael Price, MD</td>
</tr>
<tr>
<td></td>
<td>Glaucoma</td>
<td>Noelle Pruzan, MD</td>
</tr>
<tr>
<td></td>
<td>(with Chandler-Grant Lecture)</td>
<td></td>
</tr>
<tr>
<td>May 31</td>
<td>Uveitis</td>
<td>Lana Rifkin, MD</td>
</tr>
<tr>
<td></td>
<td>Macular Degeneration</td>
<td>Andre Witkin, MD</td>
</tr>
<tr>
<td></td>
<td>(with Taylor Smith Lecture)</td>
<td></td>
</tr>
</tbody>
</table>
IN MEMORIAM

B. Thomas Hutchinson, MD

April 9, 2018

President, 1996
THE BOARD AND COMMITTEES 2017-2018

The Board
John Dagianis, MD, President
Laura Fine, President-Elect
Mary Daly, MD, Vice-President;
  Chair Admissions Committee
Donna Siracuse-Lee, MD, Secretary
Jeffrey Heier, MD, Immediate Past President,
Joseph Levy, MD, Treasurer,
  Chair Finance Committee
David Lawlor, MD,
  Past President, Chair Policies and Nominating Committees
Joel Geffin, MD, Past President,
  Chair Program Committee
Michael Price, MD, Chair Educational Endowment Fund Committee
Phil Aitken MD, Chair Ophthalmic Services Committee
Brendan McCarthy, MD, Chair Public Health and Education Committee
Jorge Arroyo, MD, Chair Information Technology Committee
Michael Bradbury, MD,
  Executive Director

COMMITTEES:

Executive Committee
John Dagianis, MD, President
Laura Fine, MD, President-elect
Joseph Levy, MD, Treasurer
Michael Bradbury, MD,
  Executive Director (ex officio)

Admissions Committee
Mary Daly, MD, Chair
Laura Fine, MD
John Dagianis, MD

Finance Committee
Joseph Levy, MD Chair
John Dagianis, MD
Mary Daly, MD (ex officio)
Michael Bradbury, MD (ex officio)

Nominations Committee
Jeffrey Heier, MD, Chair
Ann Bajart, MD (MA)
Mitchell Gilbert, MD (CT)
Elliot Perlman, MD (RI)
Christopher Soares, MD (VT)
David Weinberg, MD (NH)
Charles Zacks, MD (ME)
ex officio members:
  Drs. Bradbury, Siracuse-Lee, Fine, Heier, Levy

Program Committee
Joel Geffin, MD, Chair
Fina Barouch, MD
Geoffrey Emerick, MD
Edward Feinberg, MD
Gena Heidary, MD
Jeremy Kieval, MD
Brian Kim, MD
Carolyn Kloek, MD
Robert Noecker, MD
Lawrence Piazza, MD
Shlomit Schaal, MD
Angela Turalba, MD
Michael Yoon, MD
John Dagianis, MD (ex officio)
Mary Daly, MD (ex officio)
Michael Bradbury, MD (ex officio)
Public Health and Education Committee

Brendan McCarthy, MD, Chair
Macie Finkelstein, MD
Magdalena Krzystalik, MD
Joseph Levy, MD
Robert Lytle, MD
Vasiliki Poulaki, MD
Susannah Rowe, MD
Cathryn Welch, MD
Michael Wiedman, MD
Mary Daly, MD (ex officio)
John Dagianis, MD (ex officio)

Society Policies Committee

David Lawlor, MD, Chair
John Dagianis, MD
Michael J. Bradbury, MD

Ophthalmic Services Committee

Phil Aitken, MD, Chair
Husam Ansari, MD
Timothy Blake, MD
Nicoletta Fynn-Thompson, MD
Kathryn Hatch, MD
Edward Jaccoma, MD
Marc Leibole, MD
Trexler Topping, MD
David Vazan, MD
Peter Zacharia, MD
Mary Daly, MD (ex officio)
John Dagianis, MD (ex officio)
Ralph Hinckley (ex officio)

Committee for Educational Endowment Fund

Michael Price, MD, Chair
Thomas Coghlin, MD
Francis D’Ambrosio, MD

Information Technology Committee

Jorge Arroyo, MD, Chair
Ankoor Shah, MD
David Ramsey, MD
Johanna Seddon, MD
Nauman Chaudhry, MD
Elliot Perlman, MD, (emeritus)

Young Ophthalmologists Committee

Ryan Vasan, MD, Chair
Steven Anesi, MD
Thomas Berenberg, MD
Jennifer Garvey, MD
Elizabeth Houle, MD
Daniel Lefebvre, MD
Michelle Liang, MD
Anita Nathan, MD
Joshua Ney, MD
Archana Seethala-Thangappan, MD

Jorge Arroyo, MD (ex officio)
Michael Bradbury, MD (ex officio)
Michael Price, MD (ex officio)

Judith Cerone Keenan, Executive Assistant
The New England Ophthalmological Society is one of the oldest continually meeting regional ophthalmological societies in the United States. Dedicated to education in ophthalmology and the public, as well as the highest standards in ophthalmic care and ethics, the New England Ophthalmological Society stands as a keystone of our New England ophthalmic heritage.
<table>
<thead>
<tr>
<th>Company</th>
<th>Phone Number</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbvie</td>
<td>603.493.0522</td>
<td><a href="http://www.abbvie.com">www.abbvie.com</a></td>
</tr>
<tr>
<td>Alcon – SPONSOR</td>
<td>817.615.2448</td>
<td><a href="http://www.alconlabs.com">www.alconlabs.com</a></td>
</tr>
<tr>
<td>Allergan – SPONSOR</td>
<td>714.246.4491</td>
<td><a href="http://www.allergan.com">www.allergan.com</a></td>
</tr>
<tr>
<td>Bausch &amp; Lomb – SPONSOR</td>
<td>215.671.8826</td>
<td></td>
</tr>
<tr>
<td>Bio-Tissue</td>
<td>508.808.3017</td>
<td><a href="http://www.biotissue.com">www.biotissue.com</a></td>
</tr>
<tr>
<td>Carl Zeiss Meditec</td>
<td>925.557.4158</td>
<td><a href="http://www.meditec.zeiss.com">www.meditec.zeiss.com</a></td>
</tr>
<tr>
<td>Cornea General (SightLife)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coburn Technologies</td>
<td>860.648.6708</td>
<td><a href="http://www.coburntechnologies.com">www.coburntechnologies.com</a></td>
</tr>
<tr>
<td>Diagnosys</td>
<td>978.942.4632</td>
<td><a href="http://www.diagnosysllc.com">www.diagnosysllc.com</a></td>
</tr>
<tr>
<td>Eversight</td>
<td>315.657.7059</td>
<td><a href="http://www.eversightvision.org">www.eversightvision.org</a></td>
</tr>
<tr>
<td>Genentech</td>
<td>650.467.0810</td>
<td><a href="http://www.gene.org">www.gene.org</a></td>
</tr>
<tr>
<td>Glaukos iStent</td>
<td>800.452.8567</td>
<td><a href="http://www.glaukos.com">www.glaukos.com</a></td>
</tr>
<tr>
<td>Haag-Streit USA</td>
<td>513.398.3937</td>
<td><a href="http://www.haag-streit-usa.com">www.haag-streit-usa.com</a></td>
</tr>
<tr>
<td>Heidelberg Engineering</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J&amp;J Surgical Vision - SPONSOR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KeraLink, Int.</td>
<td>410.752.3800</td>
<td>Keralink.org</td>
</tr>
<tr>
<td>Lombart</td>
<td>757.853.8888</td>
<td>Lombartinstrument.com</td>
</tr>
<tr>
<td>Mallinckrodt Pharmaceuticals</td>
<td>908.238.6758</td>
<td><a href="http://www.mallinckrodt.com">www.mallinckrodt.com</a></td>
</tr>
<tr>
<td>Marco</td>
<td>904.642.9330</td>
<td><a href="http://www.marco.com">www.marco.com</a></td>
</tr>
<tr>
<td>Microsurgical Technology</td>
<td>425.556.0544</td>
<td><a href="http://www.microsurgical.com">www.microsurgical.com</a></td>
</tr>
<tr>
<td>Notal Vision</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NovaBay</td>
<td>351.201.9593</td>
<td><a href="http://www.novabay.com">www.novabay.com</a></td>
</tr>
<tr>
<td>Novartis – SPONSOR</td>
<td>862.778.8300</td>
<td><a href="http://www.novartis.com">www.novartis.com</a></td>
</tr>
<tr>
<td>Ocular Therapeutix</td>
<td>781.357.4049</td>
<td><a href="http://www.ocutx.com">www.ocutx.com</a></td>
</tr>
<tr>
<td>OIC</td>
<td>781.341.1070</td>
<td><a href="http://www.OIC2020.com">www.OIC2020.com</a></td>
</tr>
<tr>
<td>Optovue</td>
<td>510.897.1576</td>
<td>optovue.com</td>
</tr>
<tr>
<td>Regeneron</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ScienceBased Health</td>
<td>281.885.7727</td>
<td><a href="http://www.sbh.com">www.sbh.com</a></td>
</tr>
<tr>
<td>Shire – SPONSOR</td>
<td>781.869.7620</td>
<td><a href="http://www.shire.com">www.shire.com</a></td>
</tr>
<tr>
<td>Spark Therapeutics</td>
<td>619.992.5445</td>
<td><a href="http://www.sparktx.com">www.sparktx.com</a></td>
</tr>
<tr>
<td>STAAR Surgical</td>
<td>626.303.7902</td>
<td><a href="http://www.staar.com">www.staar.com</a></td>
</tr>
<tr>
<td>Sun Ophthalmics</td>
<td>609.720.5629</td>
<td><a href="http://www.sunpharma.com">www.sunpharma.com</a></td>
</tr>
<tr>
<td>Vision Share</td>
<td>312.469.5509</td>
<td><a href="http://www.visionshare.org">www.visionshare.org</a></td>
</tr>
</tbody>
</table>
All Donors, please pick up an EEF Ribbon at registration to wear at meetings.

Diamond Patrons
$100,000 or more

Dr. Michael J. Bradbury
  In memory of Dr. C. Davis Belcher
  In honor of Dr. Hal M. Freeman
Massachusetts Eye and Ear Infirmary
  In honor of Dr. Joan Miller
Dr. and Mrs. Paul M. Pender
  In Memory of Paul D. Pender and Harry V. Carey
Dr. and Mrs. Richard J. Simmons
  In memory of Dr. Ruthanne Simmons
Ophthalmic Consultants of Boston Physicians and Patients
  In honor of Dr. B. Thomas Hutchinson

Platinum Patrons
$10,000 to $99,999

Boston Eye Research
  In memory of Dr. Sanford Hecht
Dr. John Dagianis
  In honor of Dr. Hal M. Freeman, James and Eleanor Dagianis, and Paul and Verna Dobbins
Dr. and Mrs. Stuart DuBoff
  In memory of Dr. Ruthanne Simmons
  In honor of Samuel and Gloria DuBoff and William and Diane Brown
Dr. Hal M. Freeman
Dr. Albert R. Frederick, Jr.
  In honor of B. Thomas Hutchinson
Dr. and Mrs. Joseph J. Greco
The Health Foundation of Central Massachusetts
  In honor of Dr. Michael J. Bradbury
HOYA Optical Laboratories

Gold Patrons
$3,000–$9,999

Drs. A. Robert and Jean Bellows
  In memory of Dr. W. Morton Grant
Dr. and Mrs. Paul P. Dunn
  In memory of Dr. C. Davis Belcher and in honor of Dr. A. Robert Bellows
Dr. Joel Geffin
Dr. C. Mitchell Gilbert
  In honor of Drs. Claes Dohlman, Kenneth Kenyon, and Martin Wand
Jean Keamy for the Keamy Family Foundation
  In memory of Donald and Yvonne Keamy
Maine Society of Eye Physicians and Surgeons
New England Lens Implant Society
  In memory of Dr. Sanford Hecht
Dr. and Mrs. Donald Kaplan
  In memory of Dr. Robert Vernlund
Dr. and Mrs. Elliot Perlman
  In memory of Drs. C. Davis Belcher and Kathleen Maguire
Dr. Michael Raizman
Dr. Shiyoung Roh and Mrs. Myung Ja Roh
Drs. Helen and Jack Schinazi
  In memory of Dr. C. Davis Belcher
Dr. and Mrs. John Sebestyen
  In memory of Dr. Taylor R Smith
Dr. Bradford J. Shingleton
  In honor of Drs. Albert R. Frederick, B. Thomas Hutchinson, Silvio Von Pirquet and A. Robert Bellows

Dr. B. Thomas Hutchinson
New Hampshire Society of Eye Physicians and Surgeons
Dr. Delia Sang and Dr. Mark Hughes
  In memory of Dr. Charles L. Schepens
Dr. Gerald Spindel
  In honor of Israel and Rose Spindel and Benjamin Burch
Drs. Richard and Ruthanne Simmons  
In memory of Dr. W. Morton Grant

Dr. and Mrs. Richard J. Simmons  
In memory of Drs. Paul A Chandler, W. Morton Grant, Ruthanne Simmons, and C. Davis Belcher

Dr. and Mrs. Paul Wasson  
In memory of Dr. Paul Wasson
In memory of Dr. Oscar Hollander

Dr. and Mrs. Hal Woodcome  
In memory of Dr. Harold Woodcome, Sr.
Estate of Dr. Leon Zimmerman

Silver Patrons  
$1,000–$2,999

Dr. Reid S. Appleby, Jr.  
In honor of Dr. Harold Woodcome, Jr., and Associates

Dr. and Mrs. Lloyd M. Aiello

Dr. Jorge Arroyo

Dr. William Atlee

Dr. Ann Bajart

Dr. C. Davis Belcher  
In honor of Dr. Richard Simmons

Dr. Harry Braconier  
In memory of Drs Taylor Smith, Karl Riener, Carl C. Johnson.
In honor of Dr. Hal M. Freeman

Dr. and Mrs. Sheldon M. Buzney

Children’s Hospital Ophthalmology Foundation

Dr. and Mrs. William E. Clark, Jr.

Dr. Thomas Coghlin  
In honor of Dr. Ira Asher and Dr. Kevin O’Brien

Dr. Joseph L. Dowling, Jr.

Dr. Jay S. Duker

Eye Health Services  
In memory of Dr. C. Davis Belcher

Dr. Laura Fine

Dr. and Mrs. David Greenseid

Dr. Bernard Heersink

Dr. Jeffrey Heier

Dr. Ralph Hinckley

Dr. William S. Holt

Dr. Robert T. Lacy

Dr. Joseph Levy
In honor of Dr. Thomas Hedges III

Dr. Byron S. Lingeman

Dr. Richard Low

Dr. Kathleen Maguire and Stephen Burke  
In honor of Dr. Hal M. Freeman

Dr. Lisa McHam

Dr. Clifford Michaelson  
In memory of Dr. Jesse and Mrs. Ruth Lee Michaelson

Dr. Stanislaw Milewski  
In memory of Dr. Taylor R. Smith

Dr. Peter B. Mooney  
In memory of Dr. Henry F. Allen

Dr. Paul Moulton

Dr. Stephen J. Phipps

Dr. and Mrs. Michael Price

Drs. Shiyoung Roh and John Weiter

Dr. and Mrs. George Santos

Dr. Delia Sang  
In honor of Dr. Lloyd M. Aciello

Drs. Jack and Helen Schinazi  
In memory of Mrs. Mary Santos

In honor of Dr. Irving L. Pavlo

Dr. Roger F. Steinert  
In honor of Drs. A. Robert Bellows, S. Arthur Boruchoff, Albert R. Frederick, and B. Thomas Hutchinson

Dr. J. Elliott Taylor

Dr. Felipe I. Tolentino  
In honor of Drs. Hal M. Freeman and Roland Houle

In memory of Dr. Charles L. Schepens

Dr. Trexler R. Topping

Vermont Ophthalmological Society

Dr. Martin Wand  
In memory of Dr. W. Morton Grant
EDUCATIONAL ENDOWMENT FUND DONORS (continued)

Drs. Peter Wassermann, T. Gordon Hand, Christie Morse and Bradford Hall,
In memory of Dr. John Detwiller
In honor of Dr. Lewis Stieglitz
Master William Weiter
In honor of Ann Bajart and Tony Schemmer,
and Deborah and Elliot Perlman
Dr. Kenneth Wolf
Dr. Allen Zieker

Benefactors
$500–$999

Dr. Phil Aitken
In memory of Drs. Robert Guiduli and Simmons Lessell
Drs. Elliot and Macie Finkelstein
Dr. May Daly
Dr. David Fleishman
In memory of Dr. Gary B. Fleishman
Dr. George Garcia
Dr. Robert Guiduli
In memory of Dr. Kathleen J. Maguire
Dr. Lynne Kaplinsky
Dr. Robert Lytle
Maine Eye Center
Dr. and Mrs. Howard Marton
Dr. Christopher Newton
Ophthalmic Consultants of Boston
Retina Center of Maine
Rhode Island Society of Physicians and Surgeons
Dr. Joel Schuman
Dr. Lewis Stieglitz
Dr. Dennis Stoler
Dr. Barry Wepman
Dr. Charles Wingate

Sponsors
$250–$499

Dr. Caroline Baumal
In memory of Dr. Jose Berrocal
Dr. Michael Cooper
In memory of Dr. Robert Haimovici and Dr. Behrooz Koleini
Dr. Francis Y. Falck, Jr.
Dr. Ralph A. Goodwin, Jr.
Dr. Timothy Goslee
Dr. Dana Graichen
Dr. Payson B. Jacobson
In memory of Dr. Abraham Pollen
Dr. Glenn P. Kimball
Dr. Peter Lou
Dr. Brendan McCarthy
In Memory of Dr. Behrooz Koleini
Dr. Carmen Puliaftito
Dr. Sarkis Soukiasian
In Honor of Dr. Roger Steinert
Dr. Caldwell W. Smith
Dr. Neal G. Snebold
Dr. Jonathan Talamo
Dr. Yvonne Tsai
In memory of Helena Toksoz
Dr. Andrew Wong
In memory Dr. Charles L. Schepens
Worcester Ophthalmology Associates
Dr. Charles Zacks

Friends
Up to $250

In Memory of C. Davis Belcher
Accent Eyewear
James Bernson
Dr. Charles Beyer-Machule
Philip Cacciatore
Eye Health Services
Milton Feinson
Dr. Richard Getnick
EDUCATIONAL ENDOWMENT FUND DONORS (continued)

Evelyn John
Dr. Ernest Kornmehl
Don Lesieur
Joyce Marshall
Rebecca Murphy
Therese O’Keefe
Dr. Stephen Poor, III
Eileen Rafferty
Elizabeth Reece
Dr. Richard Simmons
Marian Spilner
Dr. Ann Stromberg
Elizabeth Sullivan
Andrienne Tashjian
The Rivers School
In Memory of Dr. Peter Gudas:
   Naomi Litrowinik
   Mercedes Sayler
   Needham Psychotherapy Associates
   New England Carpenters Health Fund
   Norfolk Lodge A.F. and A.M.
   James and Jean Twynning
   Jacqueline Pepper
   Jeanne Smith
Dr. Peter Batson
Dr. Richard Brown
Dr. David Corbit
Dr. Paul Cotran
   In memory of Dr. Mariana Mead
Dr. Peter Donshik
Dr. Stuart Fay
   In honor of Dr. Michael Bradbury and
   Dr. Tuck
Melvyn and Eleanor Galin Foundation
   In honor of B. Thomas Hutchinson
Dr. Andrew Gillies
   In memory of Dr. Moshe Lahav
Dr. Timber Gorman
Dr. Jay Gooze
   In memory of Kirstyn Smith
Dr. Amy Gregory
Dr. Walter Griggs
Dr. Robert Herm

Dr. Ted Houle
Dr. Glenn P. Kimball
Dr. David Lawlor
Dr. Howard M. Leibowitz
   In memory of Dr. Behrooz Koleini
Dr. Clifford Michaelson
   In memory of Dr. Behrooz Koleini
Dr. Lawrence Piazza
Dr. Theodore Renna
Molly-Jane Isaacson Rubinger
   In honor of Trexler Topping
Dr. Donna Siracuse-Lee
Dr. Domenic M. Strazzulla
Dr. Carter Tallman
Dr. Michael Wiedman
   In honor of Dr. Claes Dohlman
MARK YOUR CALENDAR NOW

ANNUAL MEETINGS FOR OPHTHALMIC MEDICAL PERSONNEL, NURSES AND TECHNICIANS, AND OPHTHALMIC PRACTICE ADMINISTRATORS WILL BE HELD AT THE FRIDAY, SEPTEMBER 28, 2018 MEETING HYNES CONVENTION CENTER.

MORE INFORMATION AND REGISTRATION WILL BE AVAILABLE SOON AT OUR WEB SITE, WWW.NEOS-EYES.ORG